Loading…
← CockpitCompetitor Analysis › 000411.SZ Zhejiang Int'l Group Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Int'l Group Co., Ltd. Class A000411.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 71
Mkt cap
$783M
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$11.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+1.9 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥9.27
1D-0.9%
1W-5.7%
1M-4.5%
3M-7.3%
6M-21.4%
YTD-27.3%
1Y-17.3%
ATR %3.1%
52w lowhigh35.5% off high

What Zhejiang Int'l does

Employees: 3,603

Zhejiang Int'l at a glance

Size Zhejiang Int'l (000411.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $783M, the 2635th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.27 on 18 Nov 2026.

Performance Over six months the shares fell 21.4%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 19 in its peer set.

Growth Revenue grew 3.4% over the last twelve months (peer median +7.3%); the operating margin is 2.5% (peer median 12.0%).

Valuation It trades at 0.3× enterprise value to sales against a peer median of 2.6× (cheapest of 18).

Capital Return on invested capital runs 1.9 points above its cost of capital (5.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 97000411.SZ 78
Six months, rebased to 100: Zhejiang Int'l against the median of its 20 peers (local-currency closes).

Zhejiang Int'l financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥34.7BCN¥33.6BCN¥33.3BCN¥32.0BCN¥30.6B
Revenue growth—+1%+4%+5%—
Gross profitCN¥2.58BCN¥2.25BCN¥2.23BCN¥2.10BCN¥1.88B
EBITDAn/aCN¥1.18BCN¥1.12BCN¥1.01BCN¥921M
Net incomeCN¥479MCN¥501MCN¥526MCN¥489MCN¥212M
Free cash flow-CN¥483,610CN¥119MCN¥130MCN¥257MCN¥284M
Capital expenditureCN¥297MCN¥237MCN¥280MCN¥168MCN¥107M
Total debtCN¥6.26BCN¥5.88BCN¥4.33BCN¥3.52BCN¥2.96B

Quarterly statements and history in the cockpit →

Zhejiang Int'l competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%ARDX002349BLISSGVSIRWDGUD002390ORICSANOFILXRX3001RIGL688073SUVEN0024240029072171000411.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Int'l is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×250×500×750×ARDX002349BLISSGVSGUD002390SANOFILXRX688073SUVEN0024242171000411.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Int'l is the large dot.

Zhejiang Int'l competitors and peer comparison

How Zhejiang Int'l compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Int'l against its 20 peers (data as of 18 Nov 2026)
Measure000411.SZPeer medianRank in peer set
1-month return-4.5%-0.9%8th lowest of 19
6-month return-21.4%-4.7%5th lowest of 19
Distance from 52-week high-35.5%-31.2%7th lowest of 19
Revenue growth (TTM)+3.4%+7.3%9th lowest of 19
Operating margin2.5%12.0%6th lowest of 19
EV / Sales0.3×2.6×cheapest of 18
ROIC minus cost of capital+1.9 pp-0.0 pp7th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a

Questions

Which companies are Zhejiang Int'l's closest peers?
The cockpit's peer set: Ardelyx (ARDX), Jinghua Pharmaceutical (002349.SZ), Sichuan Neautus Traditional Chinese (2206.HK), Bliss GVS Pharma (BLISSGVS.NS), Bambusa Therapeutics (BBTX), Ironwood Pharmaceuticals (IRWD), Knight Therapeutics (GUD.TO), Guizhou Xinbang Pharmaceutical (002390.SZ).
Is Zhejiang Int'l expensive compared with its peers?
On ev / sales it trades at 0.3× against a peer median of 2.6×, cheapest of 18 in its peer set.
How has Zhejiang Int'l stock performed?
Over six months to 18 Nov 2026 the shares returned -21.4% against -4.7% for the median peer; over one year -17.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.